Everett, WA – February 28, 2011 – SNBL USA is hosting a session entitled “Nonhuman Primate (NHP) Infant Age and Relevance of Postnatal and Juvenile Assessments: Principles for Understanding Specific Endpoints in Study Designs Supporting Biologics Regulatory Submissions.” This presentation session will be held during the upcoming 50th Annual Society of Toxicology Meeting taking place in Washington, DC in March 2011.
In regulatory-mandated NHP pre-/post-natal and juvenile studies, infant developmental milestones and test compound pharmacology dictate the types of parameters to monitor. The pertinent question is how to identify critical parameters from the numerous possibilities that exist. Dr. Rebecca Watson, SNBL USA DART Study Director, will highlight approaches to take and provide examples of background data and interpretation.
A dedicated Question & Answer session will follow the presentation. Dr. Watson and Dr. Satoru Oneda, a fellow SNBL USA DART study director with over 25 years of CRO experience, will be available to answer attendees’ questions. Join us in Room 140B at the Walter E. Washington Convention Center on Monday, March 7th at 2:15pm for this interactive session. We look forward to seeing you in Washington, DC.
About SNBL USA, Ltd.
Headquartered in Everett, WA, SNBL USA, Ltd. is a preclinical CRO that specializes in nonhuman primate (NHP) and small animal research. Study programs range from regulatory toxicology to customized study designs and disease models. Specialized programs include reproductive toxicology, safety pharmacology, immunotoxicology and carcinogenicity. Through a commitment to investment and excellence, SNBL USA strives to offer the biotechnology and pharmaceutical industries unparalleled quality in both science and service. For additional information call 425.407.0121 or visit www.snblusa.com.
SNBL USA is a wholly-owned subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), one of the largest CROs in Japan. Established in 1957, SNBL currently employs approximately 2,000 team members worldwide and provides full service drug development capabilities ranging from preclinical through clinical services.
